Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303756 | 0.87 | ATM (0.50) | POLBTDP1L3MBTL1CYP2C9MAPT | |
| SCHEMBL10250947 | 0.82 | RAB9A (0.47) | POLBTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL11300411 | 0.82 | PTGS2 (0.50) | SMN1; SMN2POLBTDP1KDM4ENPC1 | |
| SCHEMBL1303088 | 0.82 | POLB (0.40) | POLBTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL9779069 | 0.81 | CYP1A2 (0.56) | SMN1; SMN2POLBTDP1CYP2C9CYP2C19 | |
| SCHEMBL1303442 | 0.78 | CYP1A2 (0.56) | SMN1; SMN2POLBTDP1L3MBTL1CYP2C19 | |
| SCHEMBL1304185 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP26A1TDP1CYP2C9CYP2C19 | |
| SCHEMBL2398084 | 0.75 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL1303722 | 0.74 | POLB (0.55) | SMN1; SMN2POLBMAPTKMT2A | |
| SCHEMBL5904628 | 0.73 | ATM (0.51) | PDE4DNPC1ALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8053453-B2 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1549618-A1 | PYRAZOLONE COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033433-A1 | PYRAZOLONE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | SMN1; SMN2 483/4885CYP26A1 2343/4885POLB 4263/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | SMN1; SMN2 1287/4885CYP26A1 1761/4885POLB 3909/4885 |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | MPL, PDGFRA, THPO | SMN1; SMN2 2350/4885CYP26A1 246/4885POLB 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.